Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE2

Conditions

Immune Thrombocytopenia · Treatment

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Lei Zhang, MD) · zhanglei1@ihcams.ac.cn · +8602223909009
Contact: Study coordinator (Yunfei Chen, MD) · chenyunfei@ihcams.ac.cn · +8602223909240
Ting Sun, MD (Sub-investigator)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE1, PHASE2

Tianjin, China

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE3

Créteil, France

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia

Abroad (travel likely)RecruitingPHASE2

Glendale, United States · Los Angeles, United States